ATE87659T1 - Bindungsmolekuele mit einzelpolypeptidkette. - Google Patents

Bindungsmolekuele mit einzelpolypeptidkette.

Info

Publication number
ATE87659T1
ATE87659T1 AT87906006T AT87906006T ATE87659T1 AT E87659 T1 ATE87659 T1 AT E87659T1 AT 87906006 T AT87906006 T AT 87906006T AT 87906006 T AT87906006 T AT 87906006T AT E87659 T1 ATE87659 T1 AT E87659T1
Authority
AT
Austria
Prior art keywords
single polypeptide
polypeptide chain
molecule
binding molecules
binding specificity
Prior art date
Application number
AT87906006T
Other languages
English (en)
Inventor
Robert Charles Ladner
Robert Earl Bird
Original Assignee
Enzon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Lab Inc filed Critical Enzon Lab Inc
Application granted granted Critical
Publication of ATE87659T1 publication Critical patent/ATE87659T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT87906006T 1986-09-02 1987-09-02 Bindungsmolekuele mit einzelpolypeptidkette. ATE87659T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90297186A 1986-09-02 1986-09-02
EP87906006A EP0281604B1 (de) 1986-09-02 1987-09-02 Bindungsmoleküle mit einzelpolypeptidkette
PCT/US1987/002208 WO1988001649A1 (en) 1986-09-02 1987-09-02 Single polypeptide chain binding molecules
CA000546164A CA1341364C (en) 1986-09-02 1987-09-04 Single polypeptide chain binding molecules

Publications (1)

Publication Number Publication Date
ATE87659T1 true ATE87659T1 (de) 1993-04-15

Family

ID=25671493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87906006T ATE87659T1 (de) 1986-09-02 1987-09-02 Bindungsmolekuele mit einzelpolypeptidkette.

Country Status (7)

Country Link
EP (1) EP0281604B1 (de)
JP (1) JPH02197A (de)
AT (1) ATE87659T1 (de)
CA (1) CA1341364C (de)
DE (1) DE3785186T2 (de)
DK (1) DK368588A (de)
WO (1) WO1988001649A1 (de)

Families Citing this family (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JP3105898B2 (ja) * 1988-04-16 2000-11-06 セルテック リミテッド 組換えｄｎａタンパクの製造方法
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
ATE151110T1 (de) * 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US6416971B1 (en) 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1279731B1 (de) 1991-03-01 2007-05-30 Dyax Corporation Verfahren zur Herstellung bindender Miniproteine
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08504320A (ja) * 1992-09-25 1996-05-14 コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション 標的結合性ポリペプチド
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
WO1998012334A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
GB9705376D0 (en) * 1997-03-14 1997-04-30 Harris William J Antibody fragment formulations and assay formats for detecting the presence an d concentration of analytes
JP3556459B2 (ja) 1998-03-13 2004-08-18 セイコープレシジョン株式会社 Ｅｌモジュール
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
BRPI0210579B8 (pt) 2001-06-26 2021-05-25 Amgen Fremont Inc anticorpo e composição farmacêutica
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EA033750B1 (ru) 2002-09-06 2019-11-21 Amgen Inc Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1498133A1 (de) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
PT1648998E (pt) 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
JP4777251B2 (ja) 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
WO2005068622A2 (en) 2004-01-20 2005-07-28 Merus B.V. Mixtures of binding proteins
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP1786837B1 (de) 2004-08-04 2013-05-01 Amgen Inc., Antikörper zu dkk-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007008256A (es) 2005-01-07 2007-12-06 Lexicon Pharmaceuticals Inc Anticuerpos monoclonales contra proteina 4 similar a angiopoyetina (angptl4).
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
MX2007010835A (es) 2005-03-11 2007-11-09 Sanofi Aventis Uso de mgc4504.
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
JP2008539742A (ja) 2005-05-11 2008-11-20 サノフィ−アベンティス Ｇｉｐプロモーター多型の使用
EP1888052A2 (de) 2005-05-12 2008-02-20 Wisconsin Alumni Research Foundation Blockade von pin1 verhindert die cytokin-produktion durch aktivierte immunzellen
JP5142998B2 (ja) 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
ES2409835T3 (es) 2005-11-28 2013-06-28 Zymogenetics, Inc. Antagonistas de IL-21
JP2009519983A (ja) 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
EP1987064A4 (de) 2006-02-01 2010-04-07 Arana Therapeutics Ltd Domänen-antikörper-konstrukt
JP2009534297A (ja) 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US20100105610A1 (en) 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
ES2363622T3 (es) 2006-11-17 2011-08-10 Novartis Ag Moléculas de enlace de lingo y el uso farmacéutico de estas.
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
EP2417974A1 (de) 2007-02-28 2012-02-15 Schering Corporation Kombinationstherapie zur Behandlung von Immunerkrankungen
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
NO2631248T3 (de) 2007-06-15 2018-04-14
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP2023144A1 (de) 2007-08-01 2009-02-11 Sanofi-Aventis Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
EP2589610A1 (de) 2007-08-21 2013-05-08 Amgen, Inc An menschliches C-FMS bindende antigenbindende Proteine
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615113A3 (de) 2007-08-23 2013-11-13 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
CN101910200B (zh) 2007-11-02 2013-12-18 诺华股份有限公司 改良的nogo-a结合分子及其药学用途
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
US8426153B2 (en) 2007-12-03 2013-04-23 Carnegie Mellon University Linked peptides fluorogenic biosensors
ME03057B (de) 2007-12-07 2019-01-20 Zymogenetics Inc Für IL-31 spezifische humanisierte Antikörpermoleküle
EP2105742A1 (de) 2008-03-26 2009-09-30 Sanofi-Aventis Verwendung von Kathepsin-C
EP2604280A3 (de) 2008-03-27 2013-10-16 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Hemmung von PDGFR-beta und VEGF-A
EP2334705B1 (de) 2008-09-26 2016-12-14 UCB Biopharma SPRL Biologische produkte
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2219029A1 (de) 2009-01-30 2010-08-18 Sanofi-Aventis Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
PT2403528E (pt) 2009-03-02 2016-06-08 Aduro Biotech Holdings Europe B V Anticorpos contra um ligando indutor da proliferação (april)
CN102741295A (zh) 2009-03-10 2012-10-17 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
JP5653945B2 (ja) 2009-03-10 2015-01-14 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗ｃｄ４０抗体及びその使用
JP2012520073A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
AU2010226392B9 (en) 2009-03-20 2014-05-22 Amgen Inc. Selective and potent peptide inhibitors of Kv1.3
BRPI1011195B1 (pt) 2009-05-20 2020-10-13 Novimmune S.A métodos para produzir uma coleção de ácidos nucleicos
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
EP2293072A1 (de) 2009-08-31 2011-03-09 Sanofi-Aventis Verwendung von Kathepsin H
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20120322085A1 (en) 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
WO2011063277A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EP2577309B1 (de) 2010-05-25 2016-11-23 Carnegie Mellon University Gezielte sonden für zellphysiologie
EP2575881B1 (de) 2010-05-28 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische anti-cd160-antikörper zur behandlung von augenerkrankungen auf grundlage von neoangiogenese
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
CN103282560B (zh) 2010-07-16 2016-08-03 阿迪马布有限责任公司 抗体文库
EA201370030A1 (ru) 2010-08-10 2013-06-28 Амген Инк. Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
US9879072B2 (en) 2010-10-27 2018-01-30 Amgen Inc. DKK1 antibodies and methods of use
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
UY33807A (es) 2010-12-17 2012-07-31 Sanofi Sa miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AP2013007173A0 (en) 2011-03-16 2013-10-31 Amgen Inc Potent and selective inhibitors of NAV1.3 and NAV1.7
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2688592A4 (de) 2011-03-25 2015-07-22 Baylor Res Inst Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
PH12013501924A1 (en) 2011-03-30 2017-10-25 Boehringer Ingelheim Int Anticoagulant antidotes
SG194111A1 (en) 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
KR101338517B1 (ko) 2011-04-18 2013-12-10 연세대학교 산학협력단 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
EP2518157A1 (de) 2011-04-26 2012-10-31 Sanofi Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2537532A1 (de) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
KR102171431B1 (ko) 2012-04-20 2020-10-30 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
PL3431492T3 (pl) 2012-04-27 2021-07-05 Novo Nordisk A/S Białka wiążące antygen ludzkiego ligandu CD30
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
AU2013274347B2 (en) 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
LT2922872T (lt) 2012-11-21 2018-12-27 Janssen Biotech, Inc. Bispecifiniai egfr/c-met antikūnai
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
JP6466904B2 (ja) 2013-03-15 2019-02-06 ヤンセン バイオテツク，インコーポレーテツド インターフェロンアルファ及びオメガ抗体アンタゴニスト
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
EP3013422A1 (de) 2013-06-28 2016-05-04 Amgen Inc. Verfahren zur behandlung von homozygoter familiärer hypercholesterolämie
CA2917858A1 (en) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
CN105555291B (zh) 2013-08-07 2021-08-24 助育公司 用于治疗雄性不育症的抗体、化合物及其衍生物
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CA2921639A1 (en) 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2929166C (en) 2013-11-06 2023-08-22 Janssen Biotech, Inc. Anti-ccl17 antibodies
PT3083694T (pt) 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102321168B1 (ko) 2014-08-19 2021-11-02 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
US20160067205A1 (en) 2014-09-09 2016-03-10 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016081440A1 (en) 2014-11-17 2016-05-26 Carnegie Mellon University Activatable two-component photosensitizers
KR101784451B1 (ko) 2014-12-03 2017-10-13 사회복지법인 삼성생명공익재단 뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도
HK1247221A1 (zh) 2014-12-04 2018-09-21 Janssen Biotech, Inc. 用於治疗急性髓系白血病的抗cd38抗体
US10357563B2 (en) 2014-12-18 2019-07-23 The University Of Chicago Methods and composition for neutralization of influenza
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
EP3085709B1 (de) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanisierte antikörper gegen menschliches rankl, pharmazeutische zusammensetzung und verwendung davon
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3244911T3 (da) 2015-01-12 2019-12-16 Rigshospitalet Copenhagen Univ Hospital Fremgangsmåde til bestemmelse af en sandsynlig virkning af en behandling til forbedring af mandlig ufrugtbarhed
AU2016216149B2 (en) 2015-02-06 2022-03-31 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
US10753938B2 (en) 2015-03-04 2020-08-25 The University Of Chicago Beta-catenin inhibitors in cancer immunotherapy
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
HK1253242A1 (zh) 2015-05-20 2019-06-14 Janssen Biotech, Inc. 用於治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
PE20180673A1 (es) 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
RS65347B1 (sr) 2015-06-24 2024-04-30 Janssen Biotech Inc Imunomodulacija i tretman čvrstih tumora antitelima koja specifično vezuju cd38
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
IL293065A (en) 2015-08-05 2022-07-01 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
US20190048089A1 (en) 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP4046655A1 (de) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Spezifisch an pd-1 bindende antikörper und deren verwendungen
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
EP3399989B1 (de) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3-antikörper und antigenbindende fragmente
JP2019502698A (ja) 2015-12-17 2019-01-31 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ−ｄｒに特異的に結合する抗体及びその使用
MX395677B (es) 2015-12-23 2025-03-25 Amgen Inc Proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 para usarse en trastornos metabólicos
US20170198290A1 (en) 2016-01-08 2017-07-13 Northwestern University Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
EA039594B1 (ru) 2016-02-03 2022-02-15 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
EP3418303A4 (de) 2016-02-15 2019-09-11 Samsung Life Public Welfare Foundation Antikörper gegen egfrviii und verwendung davon
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
AU2017240150C1 (en) 2016-04-01 2022-10-27 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
AU2017240667C1 (en) 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
NZ746925A (en) 2016-04-01 2023-06-30 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
DK3436030T3 (da) 2016-04-01 2022-11-21 Kite Pharma Inc Kimæriske receptorer og fremgangsmåder til anvendelse deraf
EP3445393B1 (de) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv-neutralisierende antigenbindende proteine
IL262892B2 (en) 2016-05-18 2024-04-01 Boehringer Ingelheim Int Anti pd-1 and anti-lag3 antibodies for cancer treatment
BR112018074275A2 (pt) 2016-05-27 2019-10-01 Orum Therapeutics Inc anticorpo de penetração no citosol e método de produção do mesmo
CN109416364B (zh) 2016-06-03 2022-04-12 (株)爱恩德生物 使用患者来源的肿瘤球体筛选抗体的方法
US11085930B2 (en) 2016-06-03 2021-08-10 Aimed Bio Inc. Anti-NRP1 antibody screening method
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2017209554A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 항-nrp1 항체 스크리닝 방법
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
JP2019521171A (ja) 2016-07-20 2019-07-25 ヒブリジェニクス・エスアー 抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018026249A1 (ko) 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
KR102048476B1 (ko) 2016-08-05 2019-11-26 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
EP3495391A4 (de) 2016-08-05 2020-08-19 Y-Biologics Inc. Antikörper gegen programmierten-tod-ligand 1 (pd-l1) und verwendung davon
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
MA45919A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
US20190307799A1 (en) 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018067754A1 (en) 2016-10-04 2018-04-12 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
EP3541365A1 (de) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Afliberceptformulierungen und verwendungen davon
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
BR112019012929A2 (pt) 2016-12-23 2019-12-10 Cephalon, Inc. anticorpos anti-il-5
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
JP7141405B2 (ja) 2017-02-09 2022-09-22 プロメガ コーポレイション 検体検出イムノアッセイ
CN110636861B (zh) 2017-03-03 2022-07-08 詹森生物科技公司 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
MY192630A (en) 2017-05-30 2022-08-29 Chong Kun Dang Pharmaceutical Corp A novel anti-c-met antibody and use thereof
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
EP3634443B1 (de) 2017-06-05 2024-09-18 The University of Chicago Mikrobiombiomarker des ansprechens auf eine immuntherapie: diagnostische, prognostische und therapeutische verwendungen davon
KR102692379B1 (ko) 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
BR112019025583A2 (pt) 2017-06-05 2020-06-16 Janssen Biotech, Inc. Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
AU2018288852B2 (en) 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
PT3661562T (pt) 2017-08-04 2024-12-13 Amgen Inc Método de conjugação de cys-mabs
JP7250766B2 (ja) 2017-08-25 2023-04-03 ヤンセン バイオテツク，インコーポレーテツド ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
EP4035674A1 (de) 2017-09-15 2022-08-03 Kite Pharma, Inc. Verfahren und systeme zur durchführung eines patientenspezifischen immuntherapieverfahrens mit chain-of-custody- und chain-of-identity-verfolgung biologischer proben
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
MX2020003549A (es) 2017-10-04 2020-08-03 Amgen Inc Fusiones de transtiretina e inmunoglobulina.
US11598780B2 (en) 2017-10-06 2023-03-07 The University Of Chicago Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor
JP7379347B2 (ja) 2017-10-11 2023-11-14 ジィールバイオ，インコーポレーテッド プレクチン１結合抗体およびその使用
RU2750723C1 (ru) 2017-10-20 2021-07-01 Фармабцин Инк. Антитела против vista и их применение
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
WO2019118426A1 (en) 2017-12-11 2019-06-20 Amgen Inc. Continuous manufacturing process for bispecific antibody products
KR102311838B1 (ko) 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019147822A2 (en) 2018-01-24 2019-08-01 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019169231A1 (en) 2018-03-02 2019-09-06 The University Of Chicago Methods and composition for neutralization of influenza
KR102275930B1 (ko) 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
WO2019183094A1 (en) 2018-03-19 2019-09-26 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
JOP20200259A1 (ar) 2018-04-10 2020-10-11 Kite Pharma Inc مستقبلات خيمرية لـ dll3 وطرق استخدامها
WO2019206095A1 (zh) 2018-04-24 2019-10-31 安源医药科技（上海）有限公司 针对tim-3的抗体及其用途
CN112469826B (zh) 2018-04-27 2024-02-09 (株)爱恩德生物 通过磁珠附着至细胞进行的基于磁性的生物淘选方法
WO2019217587A1 (en) 2018-05-08 2019-11-14 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
EP3569618A1 (de) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisierender cd73-antikörper
CN112166185A (zh) 2018-05-23 2021-01-01 新加坡国立大学 用于t细胞恶性肿瘤的免疫治疗的cd2表面表达和嵌合抗原受体表达的阻断
CA3101272A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Psma binding agents and uses thereof
SI3802608T1 (sl) 2018-05-24 2025-08-29 Janssen Biotech, Inc. Protitelesa anti-cd3 in njihova uporaba
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
CN118955734A (zh) 2018-07-18 2024-11-15 美国安进公司 针对steap1的嵌合受体及其使用方法
EP3830124A1 (de) 2018-08-01 2021-06-09 Cephalon, Inc. Anti-cxcr2-antikörper und verwendungen davon
KR20210040989A (ko) 2018-08-03 2021-04-14 추가이 세이야쿠 가부시키가이샤 서로 연결된 2개의 항원 결합 도메인을 포함하는 항원 결합 분자
BR112021002487A2 (pt) 2018-08-10 2021-07-27 Eutilex Co., Ltd. receptor de antígeno quimérico que se liga a hla-dr e célula car-t
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020043670A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
JP7534303B2 (ja) 2018-09-13 2024-08-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 新規のｌｉｌｒｂ４抗体およびその使用
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
KR20210077725A (ko) 2018-10-17 2021-06-25 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 투여를 제공하는 방법
AU2019370339B2 (en) 2018-11-01 2024-07-11 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
EP3880824B1 (de) 2018-11-13 2024-07-24 Janssen Biotech, Inc. Kontrolle von spurenmetallen bei der herstellung von anti-cd38-antikörpern
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
SG11202104334SA (en) 2018-11-14 2021-05-28 MediSix Therapeutics Pte Ltd Two-gene vectors for generating car-t cells and uses thereof
EP3887830A2 (de) 2018-11-28 2021-10-06 Promega Corporation Reaktive peptidmarkierung
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN116813770A (zh) 2018-12-27 2023-09-29 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3917957B1 (de) 2019-01-28 2025-11-26 Maple Biotech LLC Psmp-antagonisten zur verwendung bei der behandlung von fibrotischen erkrankungen der lunge, niere oder leber
WO2020163448A1 (en) 2019-02-06 2020-08-13 The Regents Of The University Of Michigan Chimeric antigen receptors targeting abnormal glycobiology
CA3129834A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
US20220119757A1 (en) 2019-02-15 2022-04-21 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
US20220339291A1 (en) 2019-03-06 2022-10-27 Legochem Biosciences, Inc. Antibody-drug conjugates that target dlk1 and uses thereof
US11541086B2 (en) 2019-03-14 2023-01-03 Northwestern Univeristy Compositions and methods for treating Alzheimer's disease
US11913944B2 (en) 2019-03-20 2024-02-27 Promega Corporation Photoaffinity probes
JP2022529985A (ja) 2019-04-19 2022-06-27 ヤンセン バイオテツク，インコーポレーテツド 抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法
EP3956023A1 (de) 2019-04-19 2022-02-23 Janssen Biotech, Inc. Verfahren zur behandlung von nierenkrebs mit einem anti-psma/cd3-antikörper
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
CA3144533A1 (en) 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
TWI874409B (zh) 2019-06-13 2025-03-01 美商安進公司 生物製品製造中基於生物量之自動灌注控制
JP2022536850A (ja) 2019-06-18 2022-08-19 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
US20220233685A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CN114127125B (zh) 2019-07-08 2025-01-14 安进公司 多特异性甲状腺素转运蛋白免疫球蛋白融合物
SG11202112307YA (en) 2019-07-10 2021-12-30 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7757271B2 (ja) 2019-07-15 2025-10-21 インターベット インターナショナル ベー． フェー． イヌｃｔｌａ－４に対するイヌ化抗体
BR112022001632A2 (pt) 2019-07-30 2022-04-19 Akeso Biopharma Inc Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes
US20220324971A1 (en) 2019-09-03 2022-10-13 Akeso Biopharma, Inc Anti-cd47 monoclonal antibody and use thereof
MX2022002672A (es) 2019-09-04 2022-06-16 Y Biologics Inc Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
TW202128160A (zh) 2019-10-18 2021-08-01 美國加利福尼亞大學董事會 用於治療病原性血管病症之方法及組合物
WO2021092545A2 (en) 2019-11-07 2021-05-14 Amgen Inc. Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
AU2020392245A1 (en) 2019-11-27 2022-06-23 Promega Corporation Multipartite luciferase peptides and polypeptides
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
IL293449A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
WO2021119149A1 (en) 2019-12-10 2021-06-17 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
BR112022012075A2 (pt) 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
EP4076525A4 (de) 2019-12-20 2024-05-01 Momenta Pharmaceuticals, Inc. Antikörper gegen integrin alpha 11 beta 1
JP2023508366A (ja) 2019-12-27 2023-03-02 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
WO2021201087A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
US20240183826A9 (en) 2020-04-02 2024-06-06 Chugai Seiyaku Kabushiki Kaisha Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
IL297806A (en) 2020-04-30 2022-12-01 Sairopa B V Anti-cd103 antibodies
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
WO2021234560A1 (en) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
KR20230017841A (ko) 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
CA3190649A1 (en) 2020-07-31 2022-02-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
IL300854A (en) 2020-08-25 2023-04-01 Janssen Biotech Inc Treatment of non-small cell lung cancer with EGFR mutations
KR20230069958A (ko) 2020-09-14 2023-05-19 얀센 파마슈티카 엔.브이. Fgfr 억제제 조합 요법
US20220177584A1 (en) 2020-09-16 2022-06-09 Janssen Pharmaceutica Nv Methods for treating multiple myeloma
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
TW202229350A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
JP2023546229A (ja) 2020-10-21 2023-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患の処置のためのアゴニスト性ＴｒｋＢ結合分子
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
EP4255451A4 (de) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Verfahren zur identifizierung von lilrb-blockierenden antikörpern
CA3206901A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
MX2023010633A (es) 2021-03-09 2023-11-28 Janssen Biotech Inc Tratamiento de canceres que carecen de mutaciones activadoras de egfr.
MX2023011690A (es) 2021-04-02 2023-12-15 Amgen Inc Construcciones de unión a mageb2.
IL305363A (en) 2021-04-14 2023-10-01 Akeso Biopharma Inc Anti-cd47 monoclonal antibody and use thereof
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
CN117396226A (zh) 2021-05-18 2024-01-12 詹森生物科技公司 包含t细胞重定向治疗剂和抗cd44治疗剂的组合物
WO2022246154A2 (en) 2021-05-20 2022-11-24 Dianthus Therapeutics, Inc. Antibodies that bind to c1s and uses thereof
US20240239907A1 (en) 2021-05-25 2024-07-18 Edelweiss Immune Inc C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
US20250320302A1 (en) 2021-06-09 2025-10-16 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
CN115558023A (zh) 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
US20240318114A1 (en) 2021-07-15 2024-09-26 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023015169A1 (en) 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
US20250277051A1 (en) 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
EP4384219A4 (de) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
JPWO2023053282A1 (de) 2021-09-29 2023-04-06
KR20240099227A (ko) 2021-10-18 2024-06-28 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 항-EGFR 항체, 항-cMET 항체, 항-VEGF 항체, 다중 특이적 항체, 및 이들의 용도
US20250011418A1 (en) 2021-10-29 2025-01-09 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
US20250108121A1 (en) 2021-11-09 2025-04-03 Amgen Inc. Method for producing an antibody peptide conjugate
US20230183360A1 (en) 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
AU2022409802A1 (en) 2021-12-15 2024-06-06 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
JP2025516245A (ja) 2022-04-29 2025-05-27 中山康方生物医▲藥▼有限公司 抗ヒトｉｌ－４ｒａの抗体及びその使用
WO2023215497A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN117285632A (zh) 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途
WO2024003837A1 (en) 2022-06-30 2024-01-04 Janssen Biotech, Inc. Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
PE20250669A1 (es) 2022-07-15 2025-03-04 Boehringer Ingelheim Int Moleculas de union para el tratamiento del cancer
WO2024026284A2 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
US20260042843A1 (en) 2022-08-02 2026-02-12 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
EP4584299A2 (de) 2022-09-07 2025-07-16 Quantitative Biosciences, Inc. Fentanyl-spezifische einzel-antikörper mit variabler domäne und verwendung in einem kontinuierlichen agglutinationstest
CA3264260A1 (en) 2022-09-14 2024-03-21 Amgen Inc. BISPECIFIC MOLECULE STABILIZATION COMPOSITION
WO2024079711A1 (en) 2022-10-14 2024-04-18 Janssen Research & Development, Llc Method for detection of antibody-dependent cellular phagocytosis
JP2025534180A (ja) 2022-10-21 2025-10-14 ヤンセン ファーマシューティカ エヌ．ベー． 微生物検出のための方法
WO2024084463A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using infrared spectroscopy
WO2024084461A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using raman spectroscopy
AU2023366516A1 (en) 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
CN120282797A (zh) 2022-11-02 2025-07-08 詹森生物科技公司 治疗癌症的方法
EP4615874A1 (de) 2022-11-10 2025-09-17 Immuvia Inc Zytotoxische bispezifische antikörper mit bindung an dr5 und muc16 und verwendungen davon
KR20250152696A (ko) 2022-11-21 2025-10-23 다이안서스 테라퓨틱스 오피씨오, 인코포레이티드. C1s에 결합하는 항체 및 이의 용도
TW202436348A (zh) 2022-11-25 2024-09-16 日商中外製藥股份有限公司 蛋白質的製造方法
JP2026500995A (ja) 2022-11-30 2026-01-13 インテグラル・モレキュラー・インコーポレイテッド 二重特異性形式を含むクローディン６を対象とする抗体
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
KR20250143881A (ko) 2023-01-12 2025-10-02 내셔널 유니버시티 오브 싱가포르 T 세포 및 nk 세포 악성종양의 면역요법을 위한 cd8 발현 차단 및 키메라 항원 수용체
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13
AU2024222655A1 (en) 2023-02-13 2025-08-07 Intervet International B.V. Canine antibodies to canine il-4
KR20250153845A (ko) 2023-02-28 2025-10-27 얀센 바이오테크 인코포레이티드 이중특이성 gprc5d/cd3 항체를 포함하는 조성물
EP4676947A1 (de) 2023-03-08 2026-01-14 Amgen Inc. Lyophilisierungsverfahren mit gesteuerter eiskristallbildung für bispezifische moleküle
CN120882752A (zh) 2023-03-13 2025-10-31 詹森生物科技公司 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
US20240400702A1 (en) 2023-05-09 2024-12-05 Janssen Biotech, Inc. Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024259378A1 (en) 2023-06-14 2024-12-19 Amgen Inc. T cell engager masking molecules
CN119143869A (zh) 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
WO2025094085A1 (en) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025096717A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025137093A1 (en) 2023-12-19 2025-06-26 Cephalon Llc Uses for attenuated il-2 immunoconjugates
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025153988A1 (en) 2024-01-16 2025-07-24 Janssen Biotech, Inc. Use of amivantamab to treat colorectal cancer
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025160261A2 (en) 2024-01-23 2025-07-31 Cephalon Llc Chemical dehydration and suspension delivery of protein drug products
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025226390A1 (en) 2024-04-23 2025-10-30 Cephalon Llc Use of rapamycin for improved antibody production
WO2025224679A1 (en) 2024-04-24 2025-10-30 Janssen Pharmaceutica Nv Methods and systems for microbial detection using raman and infrared spectroscopy
WO2025229538A1 (en) 2024-05-01 2025-11-06 Janssen Biotech, Inc. Materials, methods, and systems for cellular expansion of gamma delta t-cells
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
US20260041768A1 (en) 2024-05-03 2026-02-12 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025248465A1 (en) 2024-05-29 2025-12-04 Janssen Biotech, Inc. Treatment of locally advanced or metastatic egfr-mutated non-small cell lung cancer
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2025259600A2 (en) 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2026022721A1 (en) 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof
WO2026028163A1 (en) 2024-08-01 2026-02-05 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.

Also Published As

Publication number Publication date
DK368588D0 (da) 1988-07-01
EP0281604A1 (de) 1988-09-14
EP0281604A4 (de) 1990-01-08
DE3785186D1 (de) 1993-05-06
DK368588A (da) 1988-07-01
WO1988001649A1 (en) 1988-03-10
JPH02197A (ja) 1990-01-05
DE3785186T2 (de) 1993-07-15
EP0281604B1 (de) 1993-03-31
CA1341364C (en) 2002-06-04

Similar Documents

Publication Publication Date Title
ATE87659T1 (de) Bindungsmolekuele mit einzelpolypeptidkette.
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
DE69412614D1 (de) Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität
ES2070172T3 (es) Procedimiento para producir proteinas mediante adn recombinante.
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
ATE146221T1 (de) Modifikation der domäne der konstantregion der antikörpern
HRP20090517T1 (hr) Protutijela na interleukin-10
ES2184728T3 (es) Proteinas de union a la fibronectina.
CY1105161T1 (el) Ομολογα προσδεματος τιε
CY1112101T1 (el) Νευροτροφικοι παραγοντες
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
IL193886A0 (en) Antibodies that bind to ldcam sequences
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DK346385A (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
DK0789763T3 (da) ICAM-4-materialer og fremgangsmåder
DE3650692D1 (de) Rekombinantes Ricin-Toxin
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
EA200200286A1 (ru) Ген prv-1 и его применение
EA200100110A1 (ru) Нейротрофические факторы

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time